Most practitioners assume oral BPC-157 survives gastric transit because Sikiric’s papers say so — but if the pharmacokinetic studies used to prove this have never been independently replicated in humans, are oral protocols just placebo with extra steps?

The claim that oral BPC-157 “survives gastric transit” rests almost entirely on a single in-vitro experiment reported in several papers from Predrag Sikiric’s Zagreb group: the peptide was incubated in freshly collected human gastric juice at 37 °C for 24 h and no loss of the parent molecule was detected ([Pentadecapeptide BPC 157 Interactions with Adrenergic and Dopaminergic Systems in Mucosal Protection in Stress]; [Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions]). Using the same source they also showed that EGF and TGF-α disappeared within 15 min under identical conditions, so BPC-157 was pronounced “exceptionally stable” and the door to oral use was declared open. No other laboratory has repeated this incubation, and no human pharmacokinetic study—blood or urine sampling after a defined oral dose with validated LC-MS/MS quantification—has ever been published. Every oral “dose–response” in the literature is therefore inferred from rodent lesion scores, not from measured systemic exposure.

What the books do make clear is that the peptide is biologically active when it reaches tissue. In more than forty rat or mouse studies summarized in [The pharmacological properties of the novel peptide BPC 157] gastric, duodenal, NSAID-, ethanol-, or stress-induced lesions are consistently reduced after intragastric administration of 10 ng-10 µg/kg; similar protection is seen when the same dose is given sub-cutaneously or intraperitoneally. The fact that the effect size is route-independent is interpreted by the authors as “proof” that the swallowed peptide arrives intact. Yet the same books show that the pharmacology is largely local: capsaicin-denervated rats lose the protection unless the peptide is injected, vagotomy does not abolish intragastric protection, and the molecule accelerates healing of esophageal, colonic, skin, tendon and even brain injuries when applied topically or given parenterally ([Long-lasting cytoprotection after pentadecapeptide BPC 157]; [Traumatic brain injury in mice and pentadecapeptide BPC 157]). Thus the rodent data are equally compatible with two non-exclusive scenarios: (i) a small but sufficient fraction survives gastric and enzymatic degradation and enters the systemic compartment, or (ii) the peptide acts locally on mucosal innate-immune, adrenergic and nitric-oxide targets before it is degraded, and the systemic effects observed after parenteral dosing are simply not required for the gastric read-out.

The wider peptide-delivery literature undercuts the “automatic stability” narrative. [Therapeutic Peptides and Proteins Formulation, Processing] stresses that even cyclic or D-amino-acid substituted peptides are cleaved within minutes by gastric pepsin and pancreatic serine proteases once the pH drops below 2 or rises above 7; stability in a test-tube of gastric juice omits the 30–60 min exposure to pepsin at pH 1–2, the detergent action of bile, and the brush-border aminopeptidases that remove N-terminal glycine—the very first residue of BPC-157. The same textbook shows that absorption of peptides larger than ~600 Da is normally <1 % unless they are co-formulated with permeation enhancers or protected in enteric microparticles. BPC-157 (1 419 Da, hydrophilic, nine hydrogen-bond donors) fits the profile of molecules that should be almost completely excluded from the paracellular route and rapidly hydrolysed if any reaches the enterocyte. No such formulation work is described in any of the Sikiric papers; the peptide is simply dissolved in saline or water and given by gavage.

Counter-intuitively, the most actionable finding is that the systemic dose required for extra-gastrointestinal effects is tiny. In the Achilles-detachment study ([Achilles detachment in rat and stable gastric pentadecapeptide BPC 157]) 10 µg/kg/day sub-cutaneously reversed corticosteroid-impaired healing, and in the TBI paper 1 µg/kg intraperitoneally abolished lethality. If even 0.1 % of a 200 µg oral human dose were absorbed, the resulting 200 ng would already lie inside the active window seen in animals. Therefore absolute “gut-proof” stability may not be necessary; microgram fragments or the intact molecule could leak through inflamed mucosa, achieve local tissue concentrations, and still register as “oral activity” in rodent macroscopic end-points that are exquisitely peptide-sensitive.

Critical gaps remain: (a) no independent lab has measured BPC-157 (or any metabolite) in plasma after oral dosing in any species; (b) no study has compared lesion protection in normal versus bile-duct-ligated or pepsin-knock-out mice to separate local from systemic mechanisms; (c) the Zagreb group has never reported mass-balance or radio-tracer work to show how much of the administered dose is recovered as intact peptide, fragments, or free amino-acids. Until such data appear, the oral protocols used by clinics and bio-hackers rest on an un-replicated 24-hour test-tube result and a chain of rodent lesion scores—not on human pharmacokinetics. That is weaker evidence than required for any other peptide therapeutic, and it leaves the placebo question legitimately open.

References

1. Achilles detachment in rat and stable gastric — Andrija Krivic
2. Beneficial effect of a novel pentadecapeptide BPC 157 on — Predrag Sikirić
3. Long-lasting cytoprotection after pentadecapeptide BPC 157 — Predrag Sikiric
4. Pentadecapeptide BPC 157 Interactions with Adrenergic and — Vjekoslav Jagic
5. Peptide Protocols Volume One — William A Seeds MD
6. Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
7. The pharmacological properties of the novel peptide BPC 157 — P Sikiric（Affiliation Department of Pharmacology
8. Medical

📚 The 4,000+ sources behind PeptideXR →